Gil Roth07.25.11
Kathy Eddy has been named chief financial officer at BioConvergence. She will oversee the finance, HR and IT departments. The company noted that this appointment reflects the continued growth of BioConvergence and the increasing scope and complexity of the financial, personnel, and technology requirements within the pharmaceutical industry.
"We’re fortunate to have someone with Kathy’s experience, expertise and vision to join our team," said Alisa Wright, BioConvergence's chief executive officer. "She will work closely with our leadership team and business groups in aligning and expanding our capabilities to better serve our clients."
Ms. Eddy has more than 25 years of experience in finance with a concentration in taxation. In her most recent position at Lilly as director of Federal Tax and Global Tax Process, her responsibilities included Sarbanes Oxley compliance, mergers and acquisitions, income tax compliance, tax accounting and tax issue resolution. She also provided oversight for the management and planning of global tax processes including the tax research library and tax software.
"We’re fortunate to have someone with Kathy’s experience, expertise and vision to join our team," said Alisa Wright, BioConvergence's chief executive officer. "She will work closely with our leadership team and business groups in aligning and expanding our capabilities to better serve our clients."
Ms. Eddy has more than 25 years of experience in finance with a concentration in taxation. In her most recent position at Lilly as director of Federal Tax and Global Tax Process, her responsibilities included Sarbanes Oxley compliance, mergers and acquisitions, income tax compliance, tax accounting and tax issue resolution. She also provided oversight for the management and planning of global tax processes including the tax research library and tax software.